Phase 1 Clinical Trials of Polylaminin Begin This Month
15 Articles
15 Articles
A 39-year-old patient was the first of the SUS in RO to receive polylaminina Disclosure/Sesau A 39-year-old patient, a victim of a traffic accident, was the first in Rondônia to receive polylaminina by SUS, an experimental substance studied for the treatment of spinal cord injuries. The procedure was performed at the Hospital de Urgência e Emergência Regional de Cacoal (Heuro) on Monday (14). The identity of the patient was not disclosed. The St…
(images reproduction disclosure) The first phase of clinical studies with polylaminin will begin on the 24th of this month, according to the pharmaceutical company Cristália, which develops the drug in partnership with researchers from the Federal University of Rio de Janeiro (UFRJ). The substance has the potential to help people with spinal cord injury recover their...
Polylaminine will be tested in five patients for the first time. Phase 1 will evaluate the safety of the substance in humans in São Paulo.
The laboratory Cristália announced on Wednesday, 16, eight months after receiving the endorsement of the National Agency of Health Surveillance (Anvisa), that it will start the phase 1 study with polylaminine - molecule that is being tested in the treatment of spinal cord injury. From 24 September, five patients must be recruited to participate [...] The post Company announces the beginning of the study in humans of polylaminine appeared first i…
Metrópoles
gazetaweb.comPhase 1 clinical trial will assess the safety of the substance in five patients with recent spinal cord injury
Polylaminine will begin to be tested in humans on September 24, next Thursday, in a Phase 1 clinical study.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
